SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-190954
Filing Date
2022-07-11
Accepted
2022-07-11 08:54:32
Documents
15
Period of Report
2022-07-08
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d332927d8k.htm   iXBRL 8-K 32817
2 EX-1.1 d332927dex11.htm EX-1.1 180858
3 EX-5.1 d332927dex51.htm EX-5.1 8783
7 GRAPHIC g332927g0705235947493.jpg GRAPHIC 2654
  Complete submission text file 0001193125-22-190954.txt   410598

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA alna-20220708.xsd EX-101.SCH 2872
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE alna-20220708_lab.xml EX-101.LAB 19501
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE alna-20220708_pre.xml EX-101.PRE 12167
9 EXTRACTED XBRL INSTANCE DOCUMENT d332927d8k_htm.xml XML 3655
Mailing Address ONE NEWTON EXECUTIVE PARK SUITE 202 NEWTON MA 02462
Business Address ONE NEWTON EXECUTIVE PARK SUITE 202 NEWTON MA 02462 617-467-4577
Allena Pharmaceuticals, Inc. (Filer) CIK: 0001624658 (see all company filings)

IRS No.: 452729920 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38268 | Film No.: 221075960
SIC: 2836 Biological Products, (No Diagnostic Substances)